ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Daiichi Sankyo Co., Ltd.

  • 4,166.00 JPY
  • +119.00
  • +2.94%
  • Japan
    Dec 17, 2018
  • Ticker
    TKS(4568)
  • Prev. close
    4,047
  • Market cap (JPY)
    2,869.36B
  • Market cap (USD)
    25,299.72M
  • Shares
    709.01M

Business Summary

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue960,195M8,663.48M
Gross Profit614,174M5,541.46M
Operating income112,326M1,013.47M
Income before tax81,021M731.02M
Net income60,282M543.90M
EBITDA159,006M1,434.65M
Diluted EPS91.100.82
Dividends Per Share700.63
Total Assets1,897.75B17,844.41M
Total liabilities764,709M7,190.49M
Total equity1,132.98B10,653.33M
Operating cash flow108,439M978.40M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 1,118.24B 919,372M 986,446M 955,124M 960,195M
Gross Profit 715,952M 596,285M 667,824M 605,751M 614,174M
Operating income 116,938M 126,524M 154,054M 127,875M 112,326M
Income before tax 99,775M 79,936M 122,388M 87,626M 81,021M
Net income 60,943M 46,762M 82,282M 53,466M 60,282M
EBITDA 428,312M 168,547M 198,360M 175,248M 159,006M
Diluted EPS 86.41 456.62 119.11 79.44 91.10
Dividends Per Share 60 60 70 70 70
Total Assets 1,854.03B 1,982.28B 1,900.52B 1,914.97B 1,897.75B
Total liabilities 846,174M 674,973M 666,507M 743,545M 764,709M
Total equity 979,933M 1,304.05B 1,231.40B 1,175.89B 1,132.98B
Operating cash flow 37,304M 142,775M 174,281M 136,234M 108,439M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 11,163.26M 8,368.84M 8,214.61M 8,820.26M 8,663.48M
Gross Profit 7,147.26M 5,427.85M 5,561.29M 5,593.91M 5,541.46M
Operating income 1,167.37M 1,151.72M 1,282.88M 1,180.88M 1,013.47M
Income before tax 996.04M 727.64M 1,019.18M 809.19M 731.02M
Net income 608.38M 425.66M 685.20M 493.74M 543.90M
EBITDA 4,275.78M 1,534.24M 1,651.83M 1,618.35M 1,434.65M
Diluted EPS 0.86 4.15 0.99 0.73 0.82
Dividends Per Share 0.59 0.54 0.58 0.64 0.63
Total Assets 18,002.98M 16,529.38M 16,909.31M 17,185.48M 17,844.41M
Total liabilities 8,216.47M 5,628.29M 5,930.04M 6,672.75M 7,190.49M
Total equity 9,515.29M 10,873.93M 10,956.05M 10,552.78M 10,653.33M
Operating cash flow 372.40M 1,299.65M 1,451.32M 1,258.07M 978.40M

Valuation Measures

Mar 2018
PER38.61
ROA3.16%
ROE5.22%
Operating margin11.69%
Profit margin6.27%

Key executives

  • Chairman & CEO: Joji Nakayama
  • President, COO & Representative Director: Sunao Manabe
  • CFO, Representative Director & Vice President: Toshiaki Sai
  • Senior Managing Executive Officer, Head-R&D: Glenn J. Gormley
  • Executive Officer & Manager-Audit: Ryoichi Watanabe

Shareholders

  • Daiichi Sankyo Co., Ltd. (8.6%)
  • Nippon Life Insurance Co. (5.0%)
  • Capital Research & Management Co. (World Investors) (4.8%)
  • Capital Research & Management Co. (Global Investors) (4.0%)
  • Asset Management One Co., Ltd. (3.3%)
  • Nomura Asset Management Co., Ltd. (3.2%)
  • BlackRock Fund Advisors (3.1%)
  • The Vanguard Group, Inc. (2.2%)
  • Mizuho Bank Pension Fund (2.0%)
  • BlackRock Japan Co., Ltd. (1.8%)

Contact Details

  • Website:http://www.daiichisankyo.co.jp
  • Address: Daiichi Sankyo Head Office Bldg, A&B, 3-5-1 Nihonbashi-honcho, Tokyo, 103-8426, Japan
  • Phone: +81.3.6225.1111

Related Companies

  • Daiichi Sankyo Co. Ltd. /41 Long Listed Drugs Business/
  • Daiichi Sankyo Belgium SA
  • Daiichi Sankyo Restricted Stock Compensation Plan
  • Daiichi Sankyo Pharma, Inc.
  • Novare Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Shanghai) Co. Ltd.
  • Daiichi Sankyo Venezuela SA
  • Daiichi Sankyo (Schweiz) AG
  • Daiichi Sankyo Hong Kong Ltd.
  • Daiichi Forging Dalian Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Beijing) Co. Ltd.
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • Daiichi Sankyo Pension Fund
  • Daiichi Sankyo Espha Co., Ltd.
  • Daiichi Sankyo (Thailand) Ltd.
  • Daiichi Sankyo Employee Stock Ownership Plan
  • Daiichi Sankyo (China) Holdings Co., Ltd.
  • Daiichi Sankyo Ireland Ltd.
  • Sankyo Pharma Nederland BV
  • Daiichi Sankyo Taiwan Ltd.
  • NV Sankyo Pharma Belgium SA
  • Daiichi Sankyo Portugal Lda.
  • Daiichi Sankyo Nederland BV
  • Daiichi Sankyo Logistics Co. Ltd.
  • Daiichi Sankyo Italia SpA
  • U3 Pharma GmbH
  • Daiichi Sankyo Deutschland GmbH
  • Basics GmbH
  • Ranbaxy Italia SpA
  • Ranbaxy Europe Ltd.

Competitors

  • Glenmark Pharmaceuticals Limited
  • Pieris Pharmaceuticals, Inc.
  • Reata Pharmaceuticals, Inc. Class A
  • Esperion Therapeutics, Inc.
  • Assertio Therapeutics, Inc.
  • Gemphire Therapeutics Inc.
  • Catabasis Pharmaceuticals Inc
  • AbClon, Inc.
  • MacroGenics, Inc.
  • DURECT Corporation
  • Egalet Corporation
  • Loxo Oncology Inc
  • Agios Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • Deciphera Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • BeiGene, Ltd.
  • Biocon Limited
  • Fortress Biotech, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Puma Biotechnology, Inc.
  • TaiGen Biopharmaceuticals Holdings Limited
  • Aileron Therapeutics, Inc.
  • BioDelivery Sciences International, Inc.
  • Syros Pharmaceuticals, Inc.
  • UMN Pharma, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Eloxx Pharmaceuticals, Inc.
Last Updated on 17 Dec, 2018

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

{{sentenceStarter}} {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media